A Multicenter, Open-Label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF [tumour necrosis factor] Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis.

Trial Profile

A Multicenter, Open-Label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF [tumour necrosis factor] Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Planned initiation date changed from Jun 2008 to May 2008 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top